1,798 results on '"Rammensee, Hans‐Georg"'
Search Results
202. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines
203. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW
204. Two new proteases in the MHC class I processing pathway
205. Cancer Vaccines: Some Basic Considerations
206. Contributors
207. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction
208. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
209. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
210. TLR9-independent and immune complex-independent interferon α production by neutrophils upon netosis in response to circulating chromatin
211. Peptide motif of HLA-B*1510
212. Chair's Introduction
213. The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis
214. Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases
215. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation
216. Chromatin-activated neutrophils represent a major source of interferon α
217. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
218. Global Analysis of the Mammalian MHC class I Immunopeptidome at the Organism-Wide Scale
219. Integrin activation enables simultaneous and sensitive detection of functional virus-specific CD4+ and CD8+ T cells
220. Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
221. Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma
222. Going beyond clinical routine in SARS-CoV-2 antibody testing - A multiplex corona virus antibody test for the evaluation of cross-reactivity to endemic coronavirus antigens
223. SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition
224. An innovative approach for HLA typing, molecular tumor testing and the validation of tumor exclusive antigens
225. The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.
226. Designing a therapeutic SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups
227. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
228. Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies
229. Antigens in water-in-oil emulsion: a simple antigen extraction method for analysis and proof of equal antigen distribution in vaccination syringe after mixture
230. Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models
231. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
232. IMMU-08. THE ANTIGENIC LANDSCAPE OF GLIOBLASTOMA - REFINING THE TARGETS FOR IMMUNOTHERAPY
233. PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
234. The HLA-B* 1516 motif demonstrates HLA-B-specific P2 pocket characteristics
235. Cytotoxic minor histocompatibility antigen HA-1–specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction
236. Neurological symptoms in patients with biopsy proven celiac disease
237. Novel Multi-Peptide Vaccination In Hla-A2+ Hormone Sensitive Patients With Biochemical Relapse of Prostate Cancer
238. A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis
239. EpiToolKit—a web server for computational immunomics
240. Das HLA-Ligandom und Identifizierung von tumorassoziierten Antigenen in Meningeomen - der erste Schritt Richtung Peptid-Vakzinierung in Meningeomen
241. Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket
242. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1
243. On the development of personalized cancer vaccines
244. MHC ligands and peptide motifs: first listing
245. Peptide motifs of HLA-B58, B60, B61, and B62 molecules
246. Peptides Made to Order
247. Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus
248. Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer
249. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs
250. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.